38 reports

  • SANOFI
  • ASTRAZENECA

You can easily book an appointment with one online.

  • Hypertension
  • Actelion Ltd
  • AstraZeneca PLC
  • Daiichi Sankyo Company
  • Sanofi S.A.
  • Β-BLOCKER

With oral administration of candesartan cilexetil, conversion to the active compound occurs rapidly and completely during gastrointestinal absorption.

  • Hypertension
  • China
  • Demand
  • Trade
  • AstraZeneca China Inc.
  • Β-BLOCKER

Β- ADRENERGIC RECEPTORS ARE LOCATED MAINLY IN THE LUNGS, GASTROINTESTINAL TRACT, LIVER, UTERUS, VASCULAR SMOOTH MUSCLE, AND SKELETAL MUSCLE.

  • Hypertension
  • China
  • Demand
  • AstraZeneca China Inc.
  • Sanofi-Synthelabo Inc.

The auto exports exceeded over ## million each year.

  • Diagnostic Reagent
  • China
  • Demand
  • Market Size
  • Biosino Bio-Technology & Science Inc

Chest; ##(##): ##-##.

  • Hypertension
  • Therapy
  • United States
  • Actelion Ltd
  • United Therapeutics Corporation

You can easily book an appointment with one online.

  • Hypertension
  • United States
  • Actelion Ltd
  • Bayer AG
  • United Therapeutics Corporation

Candesartan cilexetil is a prodrug rapidly converted to candesartan, the active metabolite form, during absorption from the gastrointestinal tract.

  • Hypertension
  • World
  • Market Size
  • Daiichi Sankyo Company
  • Novartis AG

Jia No. ##, Hualan Ave., Xinxiang, Henan, ## P. R.

  • Diagnostic Reagent
  • China
  • Beijing BGI-GBI Biotech Co., Ltd
  • Biosino Bio-Technology & Science Inc
  • Livzon Group

Jia No. ##, Hualan Ave., Xinxiang, Henan, ## P. R.

  • Diagnostic Reagent
  • China
  • Beijing BGI-GBI Biotech Co., Ltd
  • Biosino Bio-Technology & Science Inc
  • Livzon Group
  • Product profile (late stage): Gleevec
  • CLINICAL AND COMMERCIAL ATTRACTIVENESS

These include chronic myeloid leukemia, acute lymphoblastic leukemia, and gastrointestinal stromal tumors.

  • Hypertension
  • European Union
  • North America
  • United States
  • Actelion Ltd
  • RIOCIGUAT - DRUG PROFILE

The FDA has recommended conducting one or more long-term controlled studies to assess the cardiovascular and gastrointestinal safety of naproxcinod.

  • Hypertension
  • Therapy
  • United States
  • World
  • NicOx S.A.
  • PULMONARY ARTERIAL HYPERTENSION - PIPELINE BY NIPPON SHINYAKU CO LTD, H2 2018
  • PULMONARY ARTERIAL HYPERTENSION - PIPELINE BY MEZZION PHARMA CO LTD, H2 2018

ONE PATIENT HAD A SPRYCEL-RELATED AE LEADING TO DISCONTINUATION, AND ONE PATIENT DIED FROM GASTROINTESTINAL BLEEDING UNRELATED TO TREATMENT.

  • Hypertension
  • Therapy
  • United States
  • Product Initiative
  • Actelion Ltd
  • SMALL MOLECULE TO ANTAGONIZE GABAA RECEPTOR FOR METABOLIC, GASTROINTESTINAL AND CARDIOVASCULAR DISORDERS - DRUG PROFILE
  • Phase II - Trial Details

Hypertension - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Hypertension - Pipeline Review, H1 2018, provides an overview of the Hypertension (Cardiovascular) pipeline landscape. Hypertension, also referred to as high...

  • Hypertension
  • Therapy
  • United States
  • Company
  • Anavex Life Sciences Corp.
  • Clinical Trial Profile Snapshots
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

Patients were randomized ##:##:##:## to receive ## mg of emricasan, ## mg of emricasan, ## mg of emricasan, or placebo twice daily for ## weeks.

  • Clinical Trial
  • Drug Discovery And Development
  • Hypertension
  • World
  • Product Initiative
  • LEFT VENTRICULAR DYSFUNCTION - PIPELINE BY QUANTUM GENOMICS SA, H2 2017

The final prognostic model is shown in Table ##.

  • Hypertension
  • Pharmaceutical
  • United States
  • World
  • Product Initiative
  • DORMANT PRODUCTS, H2 2018 (CONTD..3), H2 2018

The FDA has recommended conducting one or more long-term controlled studies to assess the cardiovascular and gastrointestinal safety of naproxcinod.

  • Blood Disease
  • Hospital
  • Hypertension
  • Therapy
  • NicOx S.A.
  • HYPERTENSION - PIPELINE BY SJT MOLECULAR RESEARCH SL
  • HYPERTENSION - PIPELINE BY JOHNSON & JOHNSON

The company offers over-thecounter (OTC) products for pain relief, oral health, nutrition, skin health and gastrointestinal diseases.

  • Hypertension
  • United States
  • Company
  • Product Initiative
  • HanAll Biopharma Co., Ltd.

The Minimally Invasive Therapies Group (MITG) includes the Surgical Innovations (SI) and the Respiratory, Gastrointestinal & Renal (RGR) divisions.

  • Catheter
  • Clinical Trial
  • Drug Discovery And Development
  • Hypertension
  • Medtronic, Inc.
  • PB-1046 - DRUG PROFILE

The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ##, ##, ## and ## respectively.

  • Hypertension
  • Pharmaceutical
  • United States
  • World
  • Product Initiative

One unit refers to one ultrasound catheter.

  • Catheter
  • Clinical Trial
  • Drug Discovery And Development
  • Hypertension
  • Medtronic, Inc.
  • PIPELINE BY CJ HEALTHCARE CORP, H2 2018

IT CONDUCTS RESEARCH AND DEVELOPMENT OF NEW DRUGS FOR TREATMENT OF DIGESTIVE, CANCERS, GASTROINTESTINAL CONDITIONS, INFLAMMATORY DISEASES.

  • Hypertension
  • Therapy
  • Australia
  • World
  • Product Initiative

One unit refers to one single chamber pacemaker.

  • Cardiac Management
  • Clinical Trial
  • Hypertension
  • Medical Device
  • GlobalData's company
  • Clinical Trial Profile Snapshots

Novartis AG ## ## ## ## ## ## ## ## ## ## Genextra S. p. a. ## ## ## ## ## Dr.

  • Drug Discovery And Development
  • Hospital
  • Hypertension
  • World
  • Product Initiative
  • Target
  • 5. All the trials included are unique trials.

A total of ## patients will be randomized ##:##:## into three treatment arms with standardof-care vasodilator therapies in combination with sotatercept or placebo.

  • Cardiology
  • Clinical Trial
  • Hypertension
  • Therapy
  • World
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Clinical Trial
  • Drug Discovery And Development
  • Hypertension
  • World
  • Novartis AG
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Cardiology
  • Chronic Disease
  • Clinical Trial
  • Hypertension
  • World

The FDA has recommended conducting one or more long-term controlled studies to assess the cardiovascular and gastrointestinal safety of naproxcinod.

  • Hypertension
  • Therapy
  • United States
  • Product Initiative
  • NicOx S.A.
  • NOV 01, 2017: PHASEBIO ANNOUNCES DOSING OF FIRST PATIENT IN AN EXPLORATORY CLINICAL STUDY OF PB1046 FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
  • 02/27/2018: PHASEBIO AWARDED $2.8 MILLION NIH SBIR GRANT TO SUPPORT CLINICAL DEVELOPMENT OF PB1046 IN PULMONARY ARTERIAL HYPERTENSION

The company' s deal volume increased from one pharmaceuticals & healthcare deal in 2016 to four pharmaceuticals & healthcare deals in 2017.

  • Hypertension
  • Pharmaceutical
  • United States
  • Company
  • PhaseBio Pharmaceuticals, Inc.
  • GLOBAL MARKETS DIRECT REPORT COVERAGE

Symptoms include ascites, reduced levels of platelets or white blood cells, gastrointestinal bleeding, encephalopathy or confusion and forgetfulness.

  • Hypertension
  • Therapy
  • United States
  • Product Initiative
  • Galectin Therapeutics Inc.

No grade ## gastrointestinal adverse events were reported.

  • Diabetes
  • Genitourinary System Disease
  • Hypertension
  • United States
  • Product Initiative